Latest News

• Brain Tumor Awareness Month Webinar Series        

  We have some great webinars coming up in the next few weeks for May Brain Cancer Awareness Month!

  Tuesday, May 6 (7pm ET) "Finding Clinical Trials" with Unsha Bakker, MSN, RN, OCN, CBCN, Brain Cancer Support and Solutions Alliance (BCSSA) Nurse Navigator

  Wednesday, May 7 (7pm ET) "New strategies to bypass the blood brain barrier to improve the delivery of chemotherapeutics for brain tumors" with Dr. John Boockvar

  Thursday, May 15 (6pm ET) "Fractional Tumor Burden Mapping" with Dr. Leland Hu

  Sunday, May 18 (7pm ET) "Glioblastoma: Beyond the Guidelines" with Dr. Burt Nabors
  
  You can join any or all of these webinars by visiting virtualtrials.org/webinar. No pre-registration is required!

  
  
• Discovery of FOXR2 activation in various brain tumors refines diagnosis to improve care        

  This new study from St. Jude Children’s Research Hospital shows that the FOXR2 gene—once thought to be specific to CNS neuroblastoma—is actually active in several other types of pediatric brain tumors too, including aggressive forms like high-grade gliomas and pineoblastomas. In a review of 42 brain tumors with FOXR2 activation, only a quarter were true CNS neuroblastomas. Despite similar levels of FOXR2 activity across tumor types, outcomes varied drastically: children with CNS neuroblastoma responded well to treatment, but those with gliomas or pineoblastomas had very poor survival outcomes.

  This study shows that physicians should not use FOXR2 activation as an exclusive marker for CNS neuroblastoma and instead should use comprehensive molecular testing, histology, and imaging to make accurate diagnoses and treatment plans.  

  
  
• Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy in Relapsed Brain Cancer Patients        

  In the Phase 2 IPAX-LINZ study conducted in Austria, eight patients with recurrent high-grade glioma (first or second recurrence) received intravenous TLX101 before and after second-line external beam radiation therapy (EBRT). TLX101 targets the LAT1 amino acid transporter, which is commonly overexpressed in GBM. The treatment was well tolerated, with no serious adverse events, even at higher doses than previously tested. The median overall survival was 12.4 months from treatment start, which is an improvement over the typical 9.9 months for recurrent GBM treated with EBRT alone. 

  Telix has an ongoing Phase 2 trial for TLX101 in newly diagnosed GBM (NCT05450744) in Australia, New Zealand, Austria and the Netherlands, and plans are underway for a pivotal trial in recurrent GBM which will hopefully open enrollment in Australia in late 2025 (followed by US site activation and enrollment pending FDA IND approval).